Rakuten Medical’s presentation at the J.P. Morgan Healthcare Conference 2026 delivered a clear message: the future of cancer care will be shaped not only by drugs, but by integrated platforms that pair targeted therapy with lower morbidity and broader clinical utility. Central to this strategy is photoimmunotherapy (PIT), a proprietary approach that combines tumour-targeting antibodies with a light-activated dye (IR700) and an illumination system that delivers 690 nm red light directly to the tumour. This coordinated, localised activation drives rapid tumour cell destruction while limiting damage to surrounding tissue. As both a biologic therapy and a device-enabled procedure, PIT also reflects broader trends in oncology and medtech innovation.
The platform highlights the accelerating convergence of pharmaceutical and device development. Unlike traditional small molecules or monoclonal antibodies that act solely through biochemical pathways, PIT depends on a defined delivery infrastructure, including catheters and fiber-optic light delivery. For device manufacturers, this points to growing demand for purpose-built illumination systems, interventional tools, and potentially implantable components that integrate seamlessly with biologic agents. In parallel, devices that historically played diagnostic or supportive roles are becoming therapeutic enablers, creating opportunities in device design, workflow integration, and procedure standardization.
Go deeper with GlobalData
Access deeper industry intelligence
Experience unmatched clarity with a single platform that combines unique data, AI, and human expertise.
Rakuten Medical also positioned PIT as a potential disruptor of operative workflows. In head and neck cancer, the company presented data suggesting durable complete responses in patients with recurrent disease after multiple prior therapies. Treatment sessions typically last 60-90 minutes, substantially shorter than complex salvage and reconstructive surgeries often required after conventional approaches fail. This time and invasiveness advantage matters for hospitals managing operating room capacity and total cost of care, and it strengthens the value case for procedure-based, device-enabled oncology treatments.
While near-term efforts remain focused on head and neck cancer, the underlying system is designed for expansion to other solid tumours. The acquisition of Medlight SA in 2020, continued in-house manufacturing, and development of earlier-stage assets targeting additional tumour types collectively support broader clinical deployment.
More broadly, Rakuten Medical’s strategy aligns with a shift toward platform-based medtech models. PIT is less a single product than a modular ecosystem: a biologic agent, proprietary light-delivery hardware, and procedure-specific consumables. By controlling the illumination and fiber-optic components internally, the company can iterate on the same core technology across different tumour types and anatomical settings.
Overall, the presentation underscored the continued evolution of oncology towards integrated therapeutic platforms that merge biologics, devices, and procedural innovation. By pairing clinical outcomes with signals of real-world adoption, Rakuten Medical illustrated how device-enabled therapies can aim to improve survival and quality of life while also fitting more efficiently into hospital workflows.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
